Floatz logo

Cyclophosphamide

Wiskott-Aldrich Syndrome

Roswell Park Cancer InstituteSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Wiskott-Aldrich Syndrome cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Roswell Park Cancer Institute
Phase 2BB
Evomela
Washington University School of Medicine
Phase 2BB
TACROLIMUS
Roswell Park Cancer Institute
Phase 2BB
Fludarabine
Roswell Park Cancer Institute
Phase 2BB
Thiotepa
University of Florida
Phase 2BB

View all 16 →

Same molecule, other indications

Cyclophosphamide is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
79 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
B-cell childhood acute lymphoblastic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →